Stem Cell Therapy in Limb Girdle Muscular Dystrophy

Phase 1WithdrawnNCT02050776

Neurogen Brain and Spine Institute

Overview

The purpose of this study was to study the effect of stem cell therapy on the course of the disease in patients with Limb Girdle Muscular Dystrophy.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Limb Girdle Muscular Dystrophy

Interventions

Autologous bone marrow mononuclear cell transplantationBIOLOGICAL

bone marrow derived mononuclear cells are administered intrathecally and intramuscularly in limb girdle muscular dystrophy patients

Eligibility

Sex: ALLMin age: 15 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * males and females * age group of 15 years and above * limb girdle muscular dystrophy diagnosed on the basis of clinical presentation * Electromyographic and Nerve Conduction velocity findings Exclusion Criteria: * presence of respiratory distress * presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus * malignancies * acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction \< 30% * pregnancy or breastfeeding

Locations (1)

Neurogen brain and spine institute

Mumbai, Maharashtra, India

Outcomes

Primary Outcomes

Functional Independence Measure

Time frame: 6 months

Secondary Outcomes

Manual Muscle Testing

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.